Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 35, 2017
Previous Article Next Article

Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Author affiliations

Abstract

Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood–brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

Graphical abstract: Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Back to tab navigation

Supplementary files

Article information


Submitted
16 Jun 2017
Accepted
07 Jul 2017
First published
12 Jul 2017

Nanoscale, 2017,9, 12862-12866
Article type
Communication

Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

X. Han, Z. Jing, W. Wu, B. Zou, Z. Peng, P. Ren, A. Wikramanayake, Z. Lu and R. M. Leblanc, Nanoscale, 2017, 9, 12862
DOI: 10.1039/C7NR04352J

Social activity

Search articles by author

Spotlight

Advertisements